logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Management of oral complications of disease-modifying drugs in rheumatoid arthritis.

    Article - En anglais

    Stomatitis is a troublesome adverse effect of disease-modifying anti-rheumatic drug (DMARD) therapy in rheumatoid arthritis (RA) patients.

    This review presents data to examine the incidence, clinical features and consequences of DMARD-related stomatitis, and suggests an algorithm for its clinical management.

    The specific objectives of the two studies presented here were to determine the incidence of DMARD-related stomatitis and its effect on DMARD continuation. and secondly to identify the clinical and laboratory risk factors.

    We investigated two cohorts of patients :

    (i) a retrospective survey of data collected from drug monitoring clinics run for patients on DMARDs from 1987 to 1994 involving 1539 patients and 2394 drug exposures ; (ii) a prospective study of 25 consecutive RA patients presenting with DMARD-related stomatitis compared to 29 RA controls with no history of DMARD stomatitis.

    The retrospective survey showed that 2% of DMARD patients stopped therapy because of stomatitis, but 55% of these were able to resume the same therapy.

    In the case-control study, 24% of patients discontinued temporarily and 8% permanently.

    Cases of DMARD-related stomatitis differed from controls in that they had a higher incidence of previous mouth ulcers (40% vs 14%), they smoked less (8% vs 31%) and Schirmer's test was more often abnormal (44% vs 21%). There were no differences in RA severity, disease activity or oral hygiene. (...)

    Mots-clés Pascal : Méthotrexate, Chimiothérapie, Immunodépresseur, Pénicillamine, Antirhumatismal, Toxicité, Stomatite, Infection, Herpès, Virose, Epidémiologie, Incidence, Symptomatologie, Traitement, Homme, Antifolate, Aminoacide soufré, Stomatologie, Cavité buccale pathologie

    Mots-clés Pascal anglais : Methotrexate, Chemotherapy, Immunosuppressive agent, Penicillamine, Antirheumatic agent, Toxicity, Stomatitis, Infection, Herpes, Viral disease, Epidemiology, Incidence, Symptomatology, Treatment, Human, Antifolate, Sulfur containing aminoacid, Stomatology, Oral cavity disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0320092

    Code Inist : 002B02U07. Création : 12/09/1997.